Description
Deslorelin Peptide Vials
CAS Number | 57773-65-6 |
Molar Mass | 1282.475 g·mol−1 |
Chemical Formula | C64H83N17O12 |
IUPAC Name | (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide |
Deslorelin Vials represent a sophisticated research product meticulously developed for scientific investigations, explicitly excluding any consideration for human consumption. The vials contain Deslorelin, a potent peptide, carefully synthesized to meet the highest research standards, making it an invaluable tool for various experimental applications.
Key Characteristics
Characterized by its exceptional purity and stability, Deslorelin Vials offer researchers a reliable and consistent source of Deslorelin for their studies. The formulation ensures optimal conditions for experimentation, contributing to the accuracy and reproducibility of research outcomes.
Research Applications
Deslorelin Vials find application in diverse research studies, leveraging the unique properties of Deslorelin for a wide range of experimental purposes.
Research Benefits
Deslorelin and Infertility
Studies suggest that Deslorelin may have implications in infertility research. The peptide’s ability to modulate reproductive hormones makes it a subject of interest for researchers investigating infertility-related mechanisms and potential therapeutic interventions.
Deslorelin and Precocious Puberty
Deslorelin has been explored in research focusing on precocious puberty. Preliminary studies indicate its potential to regulate the onset of puberty, providing insights for further investigations into hormonal control mechanisms.
Deslorelin and Prostate Cancer
In the realm of cancer research, Deslorelin shows promise in studies related to prostate cancer. Research suggests that the peptide may play a role in modulating hormonal pathways associated with prostate cancer, warranting further exploration into its potential therapeutic applications.
Disclaimer
This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.
Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).
Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.
Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].
IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.
References:
- Herbert, C. A., Trigg, T. E., Renfree, M. B., Shaw, G., Eckery, D. C., & Cooper, D. W. (2005). Long-term effects of deslorelin implants on reproduction in the female tammar wallaby (Macropus eugenii). Reproduction, 129(3), 361-369. Retrieved Nov 14, 2023, from https://doi.org/10.1530/rep.1.00432. [Read More]
- Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab. 1991 Dec;73(6):1235-40. doi: 10.1210/jcem-73-6-1235. PMID: 1955504. [Read More]
- Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther. 2009 Jun;8(6):1655-65. doi: 10.1158/1535-7163.MCT-08-0988. Epub 2009 Jun 9. PMID: 19509261. [Read More]
Harlan –
Great product, I am very happy with it so far. You guys never disappoint!
Jackson Hayes –
Outstanding service throughout
Mason –
Impressed by the product’s quality. The packaging was also secure